KZR
Income statement / Annual
Last year (2024), Kezar Life Sciences, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Kezar Life Sciences, Inc.'s net income was -$83.74 M.
See Kezar Life Sciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$7.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.07 M
|
$1.02 M
|
$1.51 M
|
$1.54 M
|
$1.30 M
|
$690,000.00
|
$175,000.00
|
$154,000.00
|
| Gross Profit |
$0.00
|
$5.93 M
|
-$1.02 M
|
-$1.51 M
|
-$1.54 M
|
-$1.30 M
|
-$690,000.00
|
-$175,000.00
|
-$154,000.00
|
| Gross Profit Ratio |
0
|
0.85
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$65.74 M
|
$85.70 M
|
$51.01 M
|
$38.94 M
|
$30.98 M
|
$27.36 M
|
$18.14 M
|
$6.47 M
|
$7.37 M
|
| General & Administrative Expenses |
$23.39 M
|
$26.54 M
|
$20.15 M
|
$15.72 M
|
$11.97 M
|
$9.98 M
|
$6.59 M
|
$2.28 M
|
$1.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$23.39 M
|
$26.54 M
|
$20.15 M
|
$15.72 M
|
$11.97 M
|
$9.98 M
|
$6.59 M
|
$2.28 M
|
$1.62 M
|
| Other Expenses |
$1.47 M
|
$6.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$90.61 M
|
$118.42 M
|
$71.16 M
|
$54.66 M
|
$42.95 M
|
$37.34 M
|
$24.73 M
|
$8.75 M
|
$8.99 M
|
| Cost And Expenses |
$0.00
|
$112.24 M
|
$71.16 M
|
$54.66 M
|
$42.95 M
|
$37.34 M
|
$24.73 M
|
$8.75 M
|
$8.99 M
|
| Interest Income |
$8.46 M
|
$11.10 M
|
$4.11 M
|
$188,000.00
|
$1.21 M
|
$2.26 M
|
$1.56 M
|
$232,000.00
|
$0.00
|
| Interest Expense |
-$1.59 M
|
$1.55 M
|
$1.19 M
|
$159,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
-$5.28 M
|
$1.07 M
|
$1.02 M
|
$1.51 M
|
$1.54 M
|
$1.30 M
|
$690,000.00
|
$175,000.00
|
$154,000.00
|
| EBITDA |
-$90.61 M |
-$99.25 M |
-$66.11 M |
-$52.96 M |
-$40.26 M |
-$34.42 M |
-$22.48 M |
-$8.34 M |
-$8.84 M |
| EBITDA Ratio |
0
|
-14.18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-15.03
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.87 M
|
$3.37 M
|
$2.92 M
|
$29,000.00
|
$1.21 M
|
$2.26 M
|
$1.56 M
|
$232,000.00
|
$0.00
|
| Income Before Tax |
-$83.74 M
|
-$101.87 M
|
-$68.24 M
|
-$54.63 M
|
-$41.74 M
|
-$35.09 M
|
-$23.17 M
|
-$8.52 M
|
-$8.99 M
|
| Income Before Tax Ratio |
0
|
-14.55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$2.92 M
|
-$1.35 M
|
-$2.75 M
|
-$3.56 M
|
$1.56 M
|
$0.00
|
$0.00
|
| Net Income |
-$83.74 M
|
-$101.87 M
|
-$65.32 M
|
-$53.28 M
|
-$38.99 M
|
-$31.53 M
|
-$23.17 M
|
-$8.52 M
|
-$8.99 M
|
| Net Income Ratio |
0
|
-14.55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.15 |
-1.4 |
-0.97 |
-1.01 |
-0.89 |
-1.65 |
-2.26 |
-0.65 |
-0.69 |
| EPS Diluted |
-1.15 |
-1.4 |
-0.97 |
-1.01 |
-0.89 |
-1.65 |
-2.26 |
-0.65 |
-0.69 |
| Weighted Average Shares Out |
$72.90 M
|
$72.55 M
|
$67.37 M
|
$52.76 M
|
$44.00 M
|
$19.08 M
|
$10.26 M
|
$13.02 M
|
$13.02 M
|
| Weighted Average Shares Out Diluted |
$72.90 M
|
$72.55 M
|
$67.37 M
|
$52.76 M
|
$44.00 M
|
$19.08 M
|
$10.26 M
|
$13.02 M
|
$13.02 M
|
| Link |
|
|
|
|
|
|
|
|
|
